Skip to main content

Table 1 Baseline characteristics of prospective renal transplant recipients undergoing cardiovascular risk assessment

From: Assessing cardiovascular risk in chronic kidney disease patients prior to kidney transplantation: clinical usefulness of a standardised cardiovascular assessment protocol

 

High Risk

Low Risk

 

Number

143 (61.9%)

88 (38.1%)

 

Age

59.9 ± 9.9

42.9 ± 9.8

p = 0.000

Male

81 (56.6%)

53 (60.2%)

p = 0.592

Body Mass Index (Kg/m2)

28.6 ± 5.4

26.4 ± 4.9

p = 0.003

Cholesterol (mmol/L)

4.11 ± 1.20

4.47 ± 1.22

p = 0.037

High Density Lipoprotein (mmol/L)

1.21 ± 0.47

1.28 ± 0.44

p = 0.317

Triglycerides (mmol/L)

1.68 ± 0.84

1.75 ± 1.16

p = 0.668

Parathyroid Hormone Level (pmol/L)

42.1 ± 48.9

40.5 ± 38.9

p = 0.786

C-Reactive Protein (mg/L)

9.4 ± 14.8

9.0 ± 14.7

p = 0.834

Haemoglobin (g/L)

107.8 ± 18.5

109.9 ± 15.9

p = 0.391

Ferritin (μg/L)

302.9 ± 293.9

250.5 ± 323.8

p = 0.211

Modality

p = 0.121

 Haemodialysis

54 (37.8%)

28 (31.8%)

 

 Peritoneal Dialysis

4 (2.8%)

3 (3.4%)

 Kidney Transplant

8 (5.6%)

13 (14.8%)

 No Renal Replacement Therapy

77 (53.8%)

44 (50.0%)

 Diabetes

80 (55.9%)

0 (0%)

p = 0.000

 Hypertension

135 (94.4%)

76 (86.4%)

p = 0.035

 Ischaemic Heart Disease

29 (20.3%)

2 (2.3%)

p = 0.000

 Ever smoked

54 (37.8%)

31 (35.2%)

p = 0.481

 Peripheral Vascular Disease

4 (2.8%)

0 (0%)

p = 0.113

 Cerebrovascular Accident/TIA

15 (10.5%)

1 (1.1%)

p = 0.007

 Congestive Cardiac Failure

5 (3.5%)

0 (0%)

p = 0.076

 ACEi/ARB

65 (45.5%)

34 (38.6%)

p = 0.309

 Antiplatelet

54 (37.8%)

5 (5.7%)

p = 0.000

 Beta-Blocker

43 (30.1%)

27 (30.7%)

p = 0.922

 Statin

76 (53.1%)

18 (20.5%)

p = 0.000

 Average length of follow up (days)

605.7 ± 294.8

568.5 ± 285.0

p = 0.346

  1. Results are expressed as mean ± standard deviation or number and percentage (%) where indicated. ACEi Angiotensin Converting Enzyme Inhibitor, ARB Angiotensin II Receptor Blocker, Statin HMG CoA Reductase Inhibitor